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as whooping cough, this has been one of the most persistent and 
extended infectious diseases, with more than 200 000 deaths per 
year and 20 million cases worldwide, according to  the World 
Health Organization (WHO). This situation exists today in spite of ȏ ?ȐǤ ?
of suspensions of  cells has been used since   ? ? ? ?      ?Ǥ ǡ 
about several drawbacks such as local reactions, fever and 
even some not substantiated neurological disorders has driven 
the development and application of vaccines based on isolated   ?      Ǥ  
generation of acellular vaccines (aP) containing either three or  ? ?Ǧ
other antigens, although less reactogenic, has not conferred 
the same level of protective immunity against  Ǥ  as   Ǧ  ȋȌ  ȏ ?ȐǤ  ǡ 
introduction in the 1980s has been linked to the resurgence of 
whooping cough in developed countries, where had changed 
from wP to aP vaccines. One explanation of the failure of these aP 
 ?Ǧ ?ȋǦ ?ȌǡǦ ?ȀǦ ? ?ǡ
against Ǥ. One solution to the ongoing problem might 
be a return to wP, but this is generally viewed as unfeasible in 
countries where aP vaccines are established. Therefore, a third 
generation of vaccines and new strategies regarding vaccination 
schedules and policies are in progress [3].   ǡ      
with a presentation from ǤǤ ȋǡ
Brazil), who described the development of an improved wP 
vaccine, designated as Plow, with low endotoxicity, using a  ?ǡ     Ǧǡ     Ǥ       Ǧ
(LOS) content, due to a chemical extraction of LOS from the outer 
membrane, when combined with diphtheria and tetanus antigens 
Abstract ? ?Ǧ ? ?ǡ ? ? ? ?ǡ     ǡ    Ǧȋ	Ȍǡ	     ? ǡ     ? ? ? ? ȋ ?    Ȍǡ      	  
Ȃ  ? ? ? ? ȋǡǡȌ  ? ? ? ?      ǡ
addressing topics related to the research, development, clinical 
evaluation, production and quality control of Therapeutic and 
Prophylactic Vaccines, respectively. At the same time the Workshop 
on Prophylactic Vaccines was integrated by several Symposiums, 
focused on meningococcal, pneumococcal, enteric, tuberculosis and Ǥ ? ? ?ǡ ?  ? ? ?ǡǤ
The Congress had a remarkable Opening Session, with a Key 
Lecture given by the outstanding scientist Professor Dr. Shiv Pillai ȋȌǡ   ?Ǥ
The aim of this review is to give an overview of the main topics 
discussed in the Prophylactic Vaccines Workshop, not as a complete 
narration of the events, but to provide an update of the latest state of 
the art and methodologies being applied to prophylactic vaccines with 
an expert commentary on the invited speakers.
Keywords: Vaccine;  Ǣ, 
Ǣ Combined vaccines; Enteric Vaccines; Pneumococcal 
Vaccines;  Ǣ   Typhi;
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Combined Vaccines. The Pertussis problem
The Symposium in Combined Vaccines was focused on 
research and development of pertussis vaccines as one of the 
most important components of combined vaccines. Also known 
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(DTPlow) was shown to be as potent as the current pertussis 
whole cell combined vaccine (DTP vaccine) but less reactogenic. 
The LOS extraction did not affect the integrity of the product and, 
more importantly, did not impact on the potency, immunogenicity Ȁ   Ǥ ǡ      ?
affordable alternative to currently available pertussis vaccines for 
developing countries [4]. Ǥȋǡ ǡ  Ȍ         ?  
search of improved pertussis vaccines, based mainly on outer ȋȌȏ ?ȐǤǡǤ
showed the results of the comparative characterization of wP and ȋȌǡ ?ȋǦȌ   ?  ȋ ?ǦȌ Ȁ 
well as immunogenicity in mice. Both types of vaccine raised 
strong antibody responses, but large quantitative and qualitative 
differences were measured. The highest antibody levels were   Ǥ     
 ?Ȁ
 ?Ȁ





indicate more functional antibodies were induced, although this  ?ȏ ?ȐǤ   Ǥ ×  ȋ  
ǡ
ǡȌ
on the design of new recombinant molecules comprising the  Ȁ      ȋȌǤ       ?    ? ?Ǥ ?ǡ ?
cloned in ǡǦ ? ?Ǧ ? ? ? ? ?Ȁ ? ?Ǥ ?ǡǦȀǤ        Ȁǡ
 ?
 ?Ǥǡ  ȋ ?ǦǦ ?  ?  ?Ǧ ?Ȍ    ? ȋ ?  ?Ǥ ? ? ?Ȍ Ǧ ?  Ǥ   ?ǦǦ ?  ?Ǧ ? ?Ȁ        Ǧ 
  
respect to natural Prn controls. ǤȋǡȌ
the consistency approach, the new paradigm in lot release testing 
of established vaccines. This approach starts from the idea that 
subsequent lots of vaccine produced can be compared with a Ȁ ǡ         ?  ? ȏ ?ȐǤ      
being by improvements in production and control: optimized  ǡ     Ǧ 
ȋ  Ǧ   ǡ
  cell culture techniques and bioinformatics) and a ǦǦǦȋ

ǡȌǤ    ?    ǡ           ? ǡ 
with questionable relevance, may be replaced by a battery of  Ǧǡ Ǧ    
functional tests with enhanced capacity to measure equivalence  ?ǤǤ
showed some proof of concept data of the consistency testing 
for pertussis, rabies and diphtheria vaccines [8].	ǡ Ǥ    ȋ	  ǡ
Cuba) discussed the development of a pertussis serological 
potency test (PSPT) and its correlation with protection. The ȋȌǲǳ
for Pertussis Potency in vaccines, but it has been broadly     ǡ  ? ǡ   Ǥ      ǡ  
to be a very promising alternative to the challenge method. 
However, its biological relevance, namely the mechanisms 
related to the role of the antibodies detected with protection, 
are rather unclear. Dr. Chovel showed that whole antibody ǡ    ?  ǡ   Ǥǡ
 ?
 ?
during the PSPT, suggesting a role for antibodies in inducing 
phagocytosis by phagocytes like neutrophils and macrophages. 
The results derived from an  opsonophagocytosis model        ǡ  ?  ? 
in the protection induced by wP. Thus, this alternative method ǡ
a valuable tool for estimating the biological relevance of new 
pertussis vaccines [9].
Pneumoccocal Vaccines. Learned Lessons
The main goals of the Pneumococcal Vaccine Symposium,        ? 
Pneumococcal Conjugate Vaccines (PCV) and to share with 
international experts the strategy for the development of the 
Cuban pneumococcal conjugate vaccine. 
The chairmen of the Symposium were two prestigious ǣ Ǥ  
ǡ    ǡǡǡǡǤǦǡ
   	  ǡ ǡ ǤǤ	  ǡ Ǧ
    ǡ Ǧǡ Ǥǡ Ǥ  Ʋ       ǡ Ǥ Ǥ  	ǡïǡǤ  
 ǡ     
ǡǤ ?
pneumococcal diseases around the globe, the impact of PCV on 
pneumococcal diseases and carriage, and the lessons learned  ? ? ?Ǥ
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the symposium was dedicated to update and critically review the 
development of a new PCV in Cuba.  ? ? ? ?ǡ ? ?Ǥ ?
disease were estimated to occur. Pneumococcal disease caused  ? ? ?ǡ ? ? ? ?ǡB? ? ?ǡ ? ? ?B? ? ? ?ǡ ? ? ? Ǥǡ ? ? ? 
African and Asian countries [10]. Three pneumococcal conjugate 
vaccines are licensed against Ǥ ǣ ?  ? ȋ ?ǡ Ȍ    ?ǡ  ?ǡ  ?ǡ  ? ?ǡ  ? ?ǡ  ? ?	 ? ?	Ǣ ? ? ?ȋ
ǡȌ ?ǡ ?ǡ ?ǡ ?ǡ ?	ǡ ?ǡ ? ?ǡ ? ?ǡ ? ?	 ? ?	Ǣ ? ? ? ?ȋ ?ǡȌ ?ǡ ?ǡ ?ǡ ?ǡ ?ǡ ?ǡ ?	ǡ ?ǡ ? ?ǡ ? ?ǡ ? ?ǡ ? ?	 ? ?	Ǥ   Ǧ ?      ? ? ? ?       ?   ǡ     ?      
by pneumococci. Also, a reduction of child mortality was reported   ?  ȋ)Ǧ
was documented [11, 12]. For many years in the last decade, the       Ǥ ǡǦ ? ? ? 
countries of the world, even in very poor countries thanks to the   
ǡ     ? ?    
out the vaccine [13]. On the other hand, several middle income Ǧ
ǡ
access them because of the high price of these vaccines. 
WHO recommends the inclusion of pneumococcal vaccines 
in childhood immunization programs worldwide, especially    Ǧ ?      ? ? 
1000 live births. Schedules of three primary doses (3p+0) or, 
as an alternative, two primary doses plus a booster (2p+1) are 
recommended, although the 3+1 is still used in several developed Ǥ           ?ǤǦ
pneumococcal vaccine introduction to accelerate herd protection 
and PCV impact on disease and carriage [14]. The differences 
between the 2p+1 and 3p+0 schedules are subtle, especially in 
countries with a mature immunization program in which coverage 
is high and indirect effects help enhance protection provided ȏ ? ?ȐǤ
Strong evidence was provided during the session about the  ?         Ǥ  ?   ?   ? ?Ǥ ? ? 
invasive pneumococcal disease caused by serotypes contained 
in the vaccine [11]. PCV10 has been effective against invasive ǡ ? ?ȉ ? ?ȋ ? ? ? ? ?ȉ ?Ȃ ? ?ȉ ?Ȍǡ ? ?ȉ ? ?ȋ ? ?ȉ ?Ȃ ? ?ȉ ?ȌǦȏ ? ?ȐǤ ? ? ?ǡ
inferred before licensure from an aggregate correlate of protection,    ?Ǣ  ǡ  Ǧ  Ǧ ?     ǡǡǡe 
 ? ? ?ȋ ? ?Ǧ ? ?Ȍ ? ? ? ?ȋ ? ?Ǧ ? ?Ȍ ? ?ȏ ? ?ȐǤ Ǧ     
pneumonia and mortality in different regions [18, 19].
The need of alternative PCV dosing schedules was also 
discussed during the symposium, based on the need for some 
countries to reduce cost of their immunization programs. 
ǡ
of the worlds poorest children are now receiving PCV, but the 
sustainability of this vaccination could be compromised when     
             Ǥ ò 
alǤ [20] have published a metanalysis estimating that about  ? ? ?        ? ?Ǥ ? ? ɊȀ
after two primary immunizations compared to three primary 
immunizations for most of serotypes included in one of the 
licensed pneumococcal conjugate vaccines. This difference        ?   ? ?	ǡǦ ? ?Ǥ ? ? ȋǦ ? ?Ǥ ?Ǣ Ǧ ? ?Ǥ ? ?Ȍ  Ǧ ? ?Ǥ ? ? ȋǦ ? ?Ǥ ? ?Ǣ Ǧ ? ?Ǥ ? ?Ȍ     Ǥ   ?
support the fact that the majority of children were protected 
by two primary immunizations with pneumococcal conjugate  ?ȏ ? ?ȐǤǡǦ
vaccination could be decided by some countries by changing 
the PCV schedule to single priming and a booster dose would  ?ȏ ? ?ȐǤ
option should be evaluated and clinical evidence should be 
generated for supporting this approach.
 
generation of pneumococcal vaccines. Some PCV are under   ǡ    ȋ  ? ?ǦȌǡȋ ? ?ǦȌǡ	ǡȋ ?ǦȌǡǤ   ? 
the big pharmaceutical companies to enter the PCV market,        
  ?
that can be supplied to these countries and which will cover       Ǥ ǡ
the effectiveness of PCVs has led to the development of higher 
valence vaccines, to combat in part, serotype replacement, but it 
is unclear how many serotypes can be added to a single conjugate    Ǧ    Ǥ  ǡ     ?ǡ ?Ǧ ? ? ? ?
in the target region and considerable public health impact may 
be expected [23].       Ǧ
independent immunity, but not even one has been licensed until 
now, mainly because the regulatory pathway for their licensure  ?Ǥ
 proteins such as pneumolysin toxoid ȋȌǦȋȌ
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to provide broader protection against pneumococcal disease, 
which are well tolerated and immunogenic when administered 
to healthy adults [24]. Several approaches have been followed for Ǧ Ǥ      Ǥ ? ? ?
with PhtD and dPly were immunogenic either for polysaccharide 
and protein antigens, and the investigational vaccine formulations  Ǧ        ?Ǧ       ȏ ? ?ȐǤ  ? ?
has been evaluated in combination with two pneumococcal    ǡ   ? ? ? ? ǡ  ? ? ?   ? ?
and 900 with PCV13 more PhtD and dPly proteins. This clinical       ǡ      ?     Ǧ ȋ
  ȌǤ  
has been to use pneumococcal proteins as a carrier for capsular 
polysaccharide. A clinical trial was conducted in healthy elderly 
adults to examine the safety, reactogenicity, and immunogenicity 
of six different investigational pneumococcal vaccine formulations 
containing AS02V or alum adjuvant with PhtD and dPly proteins  ?Ǧȋ ?Ȍȏ ? ?ȐǤǡǦ
correlates of protection need to be found.  ?       
the discussion and critical review of the Cuban strategy for 
the development of a heptavalent pneumococcal conjugate   ?Ǧ ȋ  ǡ ǡ   Ȍ 
the implementation of a clinical research strategy and impact 
evaluation of this new vaccine. This candidate vaccine has been           ?
human vaccine using a fully synthetic polysaccharide antigen: Ǧȏ ? ?ȐǤ ?ǦǦǤǦ ? ?Ǧ ? ?ǡ
of serotypes was kept at seven, but with a more rational selection  ?Ǣ  ?ǣ  ?ǡ  ? ?ǡ  ? ?ǡ  ?	  ? ?	       Ǧ ? ǡ   ?   ?   ǡ  
increasing the number of serotypes, and the corresponding 4 and 
9V serotypes were not included because they are found in lower    ?   ? Ǥ ǡ Ǧ ? ? ?Ǥ
strategy keeps the number of serotypes at seven, as it is considered 
the best number to get wide coverage and to enable faster vaccine 
development. The candidate vaccine contains as active ingredients      ?ǡ  ?ǡ  ?ǡ  ? ?ǡ  ? ?ǡ  ? ?	   ? ?	ǡ  
reductive amination to TT, adsorbed on aluminum phosphate as 
the adjuvant. The preclinical research stages of this vaccine have 
demonstrated immunogenicity and safety in animal models, the 
technology has been scaled up and several batches have been 
produced for clinical trials. 
The clinical research strategy and impact evaluation of this 
vaccine is based on the necessity to introduce pneumococcal         ǡ ?
the use and commercialization of this vaccine in the PCV13 era. 
The clinical evaluation strategy and impact evaluation for this 
vaccine is summarized in Figure 1.  ?Ǧ  ? ?
young adults during a controlled, randomized and double blind ǡǦ ? ?ȋ ?ǦȌ   Ǥ         ?Ǧ     
healthy adults and immunological results showed that after 
a single dose, the concentration of antibodies increased  ?       Ǧ
levels [28]. The clinical trial was published in the Cuban Public  ? ? ? ? ? ? ? ?Ǥ
Once the safety in adults was demonstrated, a controlled,  ȋ  ?ǣ ?Ȍ     ǡ 
trial was designed to assess the safety and to explore the  ?Ǧ ? ?ǡ ?Ȃ ?Ǥ
This clinical trial was designed as a bridge recommended by           ?
infants; this was the reason for the small sample of children. The 
primary outcome of this study was safety, but immunogenicity Ǥ ?Ǧ  ?     Ǥ 	 Ǧǡ        ?Ǧ ?ȋ


), and the  ?Ǧ ?   ? ?   ȏ ? ?ȐǤ     ?  ?Ǧ
the next clinical trials in children and infants. This clinical trial           ? ? ? ? ? ? ? ?Ǥ  ? ? ? ?Ǧ ? ? ? ?ǡ  ǡ ǡ Ȁǡǡ
Cuba, with the aim to demonstrate the immunogenicity and  ? ?ǦǦ ? ?Ǥǡ ? ? ? ?ǡ ?Ǧ ?ǡǡǤ ? ? ? ? ? ?ǡǡ
allow the license of the vaccine for this population.
Clinical trials in children and infants was the next stage in 
clinical evaluation of this vaccine in order to obtain a license for 
these target populations. Firstly, we evaluated the vaccine in  ?ǡ ?ǡ ? ? ?ǡ
and the results showed low reactogenicity (unpublished data).  ? ? ? ?ǡȀ ?ǦǤ  ?Ǧ        ?
for children and then for infants, with a window of a year or 
two. This time will give us the unique possibility to study the 
impact of PCV vaccination on infants and other unvaccinated 
populations [30, 31]. The current PCVs were initially introduced ǡǦǢ
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     ǡ     ǡ   ?
experience in the world where the indirect impact on infants could 
be evaluated by vaccinating with PCV in children.
The Cuban strategy will introduce vaccination of children  ?Ǧ ?Ǧ  ǡ     ? 
about the impact on reduction of nosocomial pneumonia          
unvaccinated subjects, including infants. Excellent results were ǡ	
and some other African countries based on similar strategy [30,31].
Enteric Vaccines. The promise of the future
The Enteric Vaccines (EV) Symposium received prominent 
experts and members of international programs involved in the 
development of vaccines against enteric pathogens. 	Ȁ       
major cause of childhood deaths in developing countries [32]. 
Certainly, the best strategy of control will be the improvement of 
water supplies and sanitation; however, these measures may not 
be achievable in the near future in most developing countries. For ǡǦǦ
[33].
Salmonella Typhi and Paratyphi A
Caused mainly by   serovar Typhi and 
serovar Paratyphi A, enteric fever is still an important public 
health problem in many developing countries [34]. Even though 
live attenuated and Vi capsular polysaccharide vaccines have 
been available for more than 30 years ago, almost no country 
has implemented vaccination against typhoid at country level. ǦǦ ȏ ? ?ȐǤ      ? Ǥ Paratyphi   Ǥ   ǡ     
vaccine candidates has been emerging; all focused on the ǦǤ ǡ Ǧ     ǡǦȏ ? ?ȐǤǡ
made in the development of candidates against Paratyphi A, in ȏ ? ?ȐǤ
Dr. Sushant Sahastrabuddhe, Program Leader of Enteric        ȋǡ
Korea), introduced the session with a presentation about the 
burden of typhoid and paratyphoid fever and the strategies for ǤǤǤǡ
Typhoid discussed how even though vaccines against typhoid 
have been available for several years, the absence of global  ?       Ǥǡ 
      ǤǤǡ ǡ      ǡ     
manufacturers and the clinical development plan for use in 
children less than 2 years of age. He also discussed the need of  ?ǡ
the increasing antimicrobial resistance and the non existence 
of vaccines against this disease. On the other hand, Sonsire 	ǡ	ǡ
the impact of sanitation measures and typhoid vaccination with 
Figure 1:  ?Ǧ
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ȋǦ ?ǡ	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Cuban project of development of a typhoid conjugate vaccine, ȏ ? ?ȐǤ
ETEC-Shigella-Cholera
Diarrhea remains a major cause of childhood morbidity 
and mortality worldwide [38].  ,  . and 
Enterotoxigenic  (ETEC) are among the numerous 
pathogens (bacteria, parasites and viruses) that cause diarrheal 
infectious diseases in humans. 
Together, ETEC and  Ǧ
third of annual diarrhea episodes in Africa and South Asia [39]. ǡ     Ǧ  Ǧ 
diarrhea in travelers returning from Asia, Latin America and Africa 
[40]. Currently, there are no licensed vaccines against either of 
these infectious diseases. 
Amongst the relevant antigens for vaccine development 
against ETEC are the colonization factor (CF) antigens and the heat ȋȌȋȌǤ ?Ǧ ?
CF antigens, combined with LT, may provide protection against  ? ? ?    ȏ ? ?ǡ  ? ?ȐǤ   ǡ Ǥ Thomas 
Wierzba from the Enteric Vaccine ǡ     Ǧ 
emphasizing two of the lead candidates: ETVAX (Scandinavian Ȍ   ? ? ? ȋȌǡ      ȀǤ
On th  ǡ    ?Ǧ ?   . 
that have shown clinical importance, Ǥ is highly prevalent 
globally and is the most frequent cause of travelers shigellosis 
[43].  Dr. Audino Podda, Head of the Clinical Development & 
 ȋȌǡ       
against Ǥ    
   ȋ
Ȍ
trials with encouraging results.  and ETEC, oral cholera vaccines (OCV) 
against Ǥ  have existed since the 1980s. Currently, two   ?   ȋ ? and Shanchol ?) are 
available on the international market. Both have proved to be 
safe and effective; however, the development of other OCVs using 
attenuated live strains have continued in order to confer greater  Ǧ     ǡ   ?ȏ ? ?ȐǤǡǤȋȌ	ǡǡ    ?    ? ? ? ǡ 
Cuban vaccine candidate against cholera which has accomplished Ǧ  ȋ ? ? ? ? ? ? ? ?Ȍȋ  ? ? ? ? ? ? ? ?Ȍ
Tuberculosis Vaccine
The Tuberculosis (TB) Vaccines Symposium was focused on 
the presentation of important research on global TB epidemics and 
the efforts to develop new vaccines to prevent TB. The congress         	ǡ   ǡ   Ȁ ?Ǥ
TB continues to be a central point of attention for many ǤǦ
 ȋ
Ȍ       
people since 1921, it does not confer adequate protection against    ǡ  
    ?
been shown to protect infants and young children from severe, 
often fatal complications of   ȋȌ ȏ ? ?ȐǤ            ?      
ǡǡ        ǡ
represents a global health priority.  At present, some vaccine ȏ ? ?Ȑȋ
1). Ǥ ± ǡ ȋ   Ȍǡ  
 ǡ    
applications both in humans and animals, not only for 
preventing TB infection, but also to understand the evolution  ?ǤǡǤǡǦ   ? ǡ ǡ ǡ, 
explained the status of the current development of TB vaccines, 
emphasizing the challenges and strategies related to this goal. 
Dr. Willem Hanekom, Deputy Director of TB Vaccines of Bill and 
	ǡǡǡ ?
efforts to discover new ways of developing and testing vaccine 
candidates against TB.Ǥ  ǡ    ǲÀǳǡ ǡ        
conference, speaking about TB social inequalities in health both 
in developed and developing countries.
Subsequent speakers provided an in depth view into the     ?   ǡ
presentations illuminating preclinical advances being made       ?   or 
relate  Ǥ   ǦǡǤǡǲǳ±ǡ
use of an attenuated mutant of Ǥ   ? ? 
the sigma factor E as a live vaccine in an experimental model      Ȁ     Ǥ Ǥ Ǧ     Ǧ     
dose of this mutant, showed higher survival rates and less tissue 
damage than animals infected with the parental strain. Although 
animals infected with the mutant had low bacillary loads,     ?        ȋ	ǦɀȌǡ  ȋ	ǦȽȌǡȋȌǡǦ
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ȏ ? ?ȐǤǡ
that the mutant, when inoculated subcutaneously, was more 
 ?ǡ
as a subcutaneous vaccine, induced a higher level of protection 
 ? ?
strain of Ǥȋ ? ? ? ? ? ? ?ȌǤ
more attenuated vaccine strain they produced a second mutation 
in the gene  ? ? that contributed to the production of the     ȋȌǡ 
the double Ȁ ? ?  ȋ ȌǤ  Ȁǡ
attenuation in  ? ? single mutant induced less tissue damage 
than the parental strain. When used as a subcutaneous vaccine,  ? ?       
strain of Ǥ  ȋ   ? ? ? ? ? ? ?Ȍǡ  
Ǥ  ?
suggested that this double mutant is a very promising strain for 
the development of a new vaccine against TB.  ǡ    ǲ Àǳǡ
Cuba, described her experiences using Ǥ ƲƲ   Ǥ
by the vaccination with either a live, inactivated or protein fraction 
of Ǥ ƲƲ Ǧ  ? ? ? ?      
signs in experimental models. Ǥ ƲƲ Ǧ  ? ? ? ?  
naturally attenuated strain which allows total animal survival and 


vaccination [48]. ǡ     
  ǡ	ǡ
proteoliposome and lipǦ
mycobacteria as promising candidates to be considered as a new ȏ ? ?ȐǤ
from mycobacteria were obtained using the experience and 	ȏ ? ?ȐǤǤ
ǡǤ
ȏ ? ?ǡ ? ?Ȑȏ ? ?ȐǤ
demonstrated the capacity to induce cellular and humoral immune    ǡ  Ǧǡ Ǥ  ȏ ? ?ǡ ? ?ȐǤ
from Ǥ  ȋ Ȍ  
 ȏ ? ?Ȑ 
protection as a prophylactic vaccine against intratracheal infection 
with Ǥ   ? ?ǡ     
alum.. ǡ
as poster presentations, including the protective capacity of 
liposomes obtained from Ǥ   Ȁ   ? ?ȏ ? ?ȐǢ ?ȏ ? ?ȐǢ    ȏ ? ?ȐǢ     Ǧ
against cell wall lipoarabinomannan of Ǥ.
This symposium represented a unique opportunity to 
interchange experiences, results, alternatives and strategies 
relevant to the evaluation of new TB vaccine candidates       
 
and to develop TB vaccines for use in adolescents and adults. 
Additionally, the congress provided an important opportunity ǡ ?.
Vaccines against meningococcal disease; status and 
perspectives ?ǡ
and pharma.  The discussion was focused on the current 
situation of meningococcal vaccines, being the multivalent 
conjugated polysaccharide vaccines and the recently licensed 
antimeningococcal serogroup B vaccines. From the early ǡ ? ? ? ?ǡ
there has been a gradual improvement in vaccines that have 
the bacterial polysaccharide (PS) capsule as the protective ǣ  ?   ?     ǡ
then as combinations for protection against an increased       Ǥ  ǡ   Ǧ     ? 
quadrivalent conjugate formulations, against meningococcal  ǡ ǡ         
important vaccine strategies ever implemented against these  ȏ ? ?Ǧ ? ?ȐǤ     
are listed in Figure 2. The public health impact of the various ȏ ? ?ǡ ? ?ȐǤǡ  ǡ      
for meningococcal conjugate vaccination, the importance of 
immunization schedules and concomitance studies to optimize 
the induction of immunological memory, protection and 
protective herd immunity against meningococcus.Ƭ        Ǥ  	 ȋ   Ȍ. Dr. LaForce also 
in some African countries. This conjugated vaccine against Ǥ
 serogroup A has become an affordable solution for 
developing countries of Africa against epidemics caused by this 
Figure 2: A dream coming through; in 2013 it became possible 
to prevent meningococcal disease caused by all major serogroups 
ȋǡ
 ? ? ? ?ȌǤ
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meȏ ? ?ǡ ? ?ȐǤǡ
will be needed to demonstrate the impact of the new pentavalent 
vaccine candidate in Africa. ǡ                 ȏ ? ?ǡ  ? ?ȐǤ
Early on during the development of meningococcal vaccines, it was 
due to molecular mimicry with glycoproteins found in human 
tissue (especially abundant in the fetal brain). Efforts to break 
immunological tolerance raised concerns regarding potential 
autoimmunity reactions and tissue damage in vaccinees in general 
and pregnant women in particular. Thus, vaccine development  ?Ǧȏ ? ?ǡ ? ?ȐǤ  ǡ      ȋȌǡǡ
Symposium with a dissertation about the learning points from     Ǥ    ? ? ? ?ǡ  ǦǦ
demonstrated protection against the respective outbreak strain in 
these two countries. Due to the work of international collaborations, 
involving WHO, Pan American Health Organization (PAHO) and Ǥ       ȋǡ Ȍǡ 
became clear that protection after primary immunization with two 
doses was of fairly short duration and a booster was needed after   ȏ ? ?ȐǤ          Ǧ  ?  ǡ     ȏ ? ?ȐǤ     ?ǡȏ ? ?ȐǤ
However, the international collaborations and exploratory 
appear ? ? ? ?ȏ ? ?ȐǤ               ȏ ? ?ȐǤ            Ǧ
controlled trial, so after initial safety and immunogenicity studies, Ǧ ?Ǥ ?
inhabitants less than 20 years of age (later four doses for infants) ȏ ? ?ǡ ? ?ȐǤ ? ? ? ǦǡǦ  Ǧ      ȏ ? ?ǡ ? ?ȐǤ          
coverage, a number of approaches have been explored; from Ǧ       ǲǦǳ    ȋȌ  
minor outer membrane proteins that were assumed to be under      ȏ ? ?ǡ  ? ?ǡ  ? ?ȐǤ   ?
substantial breakthrough occurred in 2000 by sequencing the 
whole genome of a Ǥ  strain and using the    ǡ    ȏ ? ?ȐǤ 
developed according to these principles was ready 13 years later 
 ?ȋ ?, 
Ȍȏ ? ?ǡ ? ?ȐǤ    ǣ  Ǧ ȋȌǡ  Ǧ  ȋȌȋȌ ȋ ?Ǥ ?Ȍȏ ? ?ǡ ? ?ȐǤ
fact the same vaccine component that was used for controlling Ǧ
from 2004 to 2008, mentioned above.  ǡ    ǡ 
of fractionation of bacterial extracts and immunological 
measurements, led to the development of another protein based ǡ ? ? ? ? ? ȋȀ ?Ȍ ȏ ? ?ǡ  ? ?ȐǤ     
two lipidated variants of fHbp, which are claimed to cover most   Ǥ     
a key protective antigen and have demonstrated broad strain  ? ? ? ? ? ?ǡȏ ? ?Ǧ ? ?ȐǤ  ? ? ? ?ǡ  Ǧ      ?
most circulating serogroup B of Ǥ  ȋȌ
(ǣȀȀǤȀ ? ? ? ?Ȁ ? ?Ȁ ?ȀǦǦǦǦǦǦǦ and ǣȀȀǤǤǤȀȀǤǫ éȀȀȀȀ ? ? ? ? ? ?Ȁ ? ? ? ? ? ? ? ?ǤƬ é ? ? ? ? ? ? ? ? ? ? ? ?).   ?       ȋ Ȍ   ?      ?,  Ǥ   ? ? ? ?      ǡ   ?ȋ ? ? ? ?ǡ ?ȌȋǣȀȀǤda.ȀȀȀȀ
ucm421020.htm).  Thus, the vision of vaccinating against all  Ǧ      ȏ ? ?ȐǤ      
required more than 20 years of research, and they represent a Ǥ ?Ǧ
that are not dependent on toxin neutralization as a key preventive 
principle. This historical use and integration of knowledge in the  ?
of other vaccines in the years to come. Learning points that will 
be particularly useful, also in more general settings, include 
selection of strain panels and evaluation of strain coverage 
for a particular vaccine formulation. Challenges of making      ?  Ǧ ? ? ? ? ? ?Ǥ ?ǡ
development and the initial attempts to implement the vaccine 
in national vaccination programs, also illustrated limitations      Ǧ   ?ǡȏ ? ?ǡ
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 ? ?ȐǤǡ ? ? ? ? ? was introduced in ȋǣȀȀǤǤȀǦ;ǣȀȀǤ ?ǤȀȀǦ ?ǦǦǦǦǦ ? ?ǦȀ ? ? ? ?Ǧ ? ?Ǧ ? ?) [88]. ?
impact and value of these new meningococcal vaccines in various Ǥ
duration of protection in various age groups, mucosal immunity 
and herd protection. Of particular note, a substantial difference in 
immunogenicity has been observed with recombinant fHbp versus ǦȋǦǦ ?Ǧ ?Ȍȏ ? ?Ǧ ? ?ȐǤ ? ? ?ǡ Ǧ     Ǥ    Ǧ     
manufactured without using the standard detergent extraction        ȏ ? ?ȐǤ
manipulation of LPS ( ?ǦȌȏ ? ?ȐǤtitres and broader 
immune responses, resulting in better capacity to kill strains with 
fHbp variants that are substantially different from the vaccine      ȏ ? ?ǡ ? ?Ǧ ? ?ȐǤ  Ǧ     ǲǳ    Ǥ       ?    ?       Ǧ ǡ 
ȏ ? ?Ȑ
alternatives in existence, against like Ǥȏ ? ?ȐǤ ǡ       
ongoing. The results of a collaborative project between Finlay          
ȋȌǡ    ȋȌ    ȋȌǤ         
formulation from meningococcal serogroups A and W demonstrate      ȋ    ? ? ? ? ? ? ? ?ȌǤǡǡ
discussed as an alternative to developing an affordable vaccine for 
African countries [98].
Thus, in the current situation there are strong indications for       Ǧ  
ways for modern biotechnology and vaccinology, in the decades 
to come (Figure 2). 
Improving vaccination for all people
A general Symposium was dedicated to review recent strategies 
for the sustainable development of vaccines. Dr. Pagliusi, Executive      ǯ ȋȌǡ     
for improving vaccination to all people: The common mission of 
         
emerging infectious diseases, by improving the availability  Ǧ  Ǥ   ǡ Ǧǡ Ǧǡ ǦǦ ?ǡ  
driven alliance of vaccine manufacturers, research and policy 
organizations from all over the world, it operates based on        ?ǡ
technical and economic cooperation, guided by common values 
of equity, responsibility, accountability, transparency and 
respect. 
Developing countries economies include all countries that 
Figure 3: The results represent averages of those countries for which 
urban Demographic and Health Surveys (DHS) data were available  ? ? ? ? ?Ȃ  ? ? ?ȋ é ? ?
countries, Americas=8 countries, Asia=14 countries, Europe=2 counǦ
tries).
Figure 4: 
     
working together to carry out vaccination for all people
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 ?   ȋȌ	ȋ ? ? ? ?ǡ	 Ǥ ǣȀȀǤǤȀȀȀȀȀ ? ? ? ?Ȁ ? ?ȀȀǤ) based on three main criteria: economic, education    ȋ	  ?ȌǤ ǡ    ǡ
most central European, Oceania countries and Japan, all other 
countries are considered developing economies. Thus, the network  ? ? ? ?
territories, divided in three major regions: Latin America with 8 ǡǦǦ ?ǡǦ ?   ? ? ǡ      
respective regional populations. All manufacturers operate with 
the approval of local regulatory authorities and 11 manufacturers  ?ǡǤ
challenge is to satisfy the needs of developing country populations,  ? ? ?ǯ
is growing at a fast pace with high birth rates in many countries, 
with 1 billion people growing from 2000 to 2012, and estimated to  ? ? ? ? ?Ǥǡ
are on the rise, particularly in developing countries, where DTP         ? ? ?      ? ? ?  ?ȋ	 ?ȌǤ       
immunization programs, the manufacturers have contributed  ?        
eradication, tetanus elimination, measles and rubella elimination, 
and to supply vaccines such as yellow fever, typhoid fever, 
meningitis A, Japanese encephalitis, and Hepatitis E vaccines, 
diseases predominantly relevant on a regional basis.
By sharing the common goals of increasing and maintaining 
the number of vaccines available for international procurement,   
Ǧ ǡ        ? ǡ   ǡ       
support manufacturers, as follows: 1) review the design and layout         ?  





3) create a forum for industry to discuss regulatory challenges 
with experts; 4) to create a database of expert vaccine consultants  ?ǯǤ
The new initiatives are expected to have an impact on upgrading 
facilities for priority vaccines, provide consistent information        
ǡǦ ?ǡǲǳǡ    ? 
countries, and facilitate access to reliable consulting expertise 
for members to advance with clinical development, regulatory ǡ   Ǥ   
efforts in trying to engage members and partners in contributing 
to the global initiatives.ǡ ?ǦǦ ?
vaccines in developing countries has grown 10 fold in the last  ? ? ǡ   ? ?   ? ? ?     	ǡ ?ǡ ? ?

countries have introduced this vaccine today as compared to  ?Ǧ ? ? ? ? ?Ǥ
true for rotavirus, pneumococcal and HPV vaccines, among 
others, when more manufacturers can make them available. 
Vaccines have proven to be an effective strategy in controlling, 
eliminating and eradicating infectious diseases, as a result of 
close cooperation and partnerships.
Still much remains to be achieved, as while the global 
coverage of essential traditional vaccines such as DTP, hepatitis ǡ ? ? ? ? ? ? ?ǡ
new vaccines such as pneumococcal and rotavirus vaccines is  ? ? ? ? ?ǡ
less. The needs are huge as populations in developing countries 
continue to grow and so we need strong manufacturers to take 
up this challenge and scale up the supply of affordable vaccines 
to control and prevent the spread of infectious diseases globally.         
and partners in contributing to the global initiatives. 
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